Across TCGA pan-cancer cohorts, TMEM167B mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated TMEM167B data layer compared with 25 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMEM167B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TMEM167B expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.

HNSC, LSCC, and CCRCC are the cancer types where TMEM167B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	All	0.931	0.716	.005	13	view →
LSCC	OS	Median	II,III,IV	0.871	1.000	.015	11	view →
CCRCC	OS	Tertile	IV	0.067	1.000	.036	7	view →
LUAD	DFS	Median	II,III,IV	0.911	0.795	.023	6	view →
PDAC	OS	Median	III,IV	0.363	0.743	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: TMEM167B tumor-vs-normal RNA expression · all TMEM167B data types